{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:09:05Z","timestamp":1784664545751,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cgh.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:25:38Z","timestamp":1760538338000},"page":"1654-1665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis\/Crohn\u2019s Disease: A Prospective Observational Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Edouard","family":"Louis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Moum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Angellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Adsul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.10.006_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/phrs.2021.1603990","article-title":"A review of inflammatory bowel disease: a model of microbial, immune and neuropsychological integration","volume":"42","author":"Tavakoli","year":"2021","journal-title":"Public Health Rev"},{"key":"10.1016\/j.cgh.2025.10.006_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.10.006_bib3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.10.006_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/MIB.0000000000001060","article-title":"Patient-reported outcomes of quality of life, functioning, and GI\/psychiatric symptom severity in patients with inflammatory bowel disease (IBD)","volume":"23","author":"IsHak","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.10.006_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.714057","article-title":"Depression and anxiety disorders in patients with inflammatory bowel disease","volume":"12","author":"Hu","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.cgh.2025.10.006_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.10.006_bib7","article-title":"INN-vedolizumab summary of product characteristics","volume":"2023","year":"2022","journal-title":"Takeda Pharma A\/S"},{"key":"10.1016\/j.cgh.2025.10.006_bib8","article-title":"Prescribing information","year":"2022","journal-title":"Takeda Pharmaceuticals America"},{"key":"10.1016\/j.cgh.2025.10.006_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.10.006_bib10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.10.006_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.10.006_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.10.006_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.10.006_bib15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.10.006_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.10.006_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.10.006_bib18","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.10.006_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000503099","article-title":"Management of the elderly inflammatory bowel disease patient","volume":"101","author":"Hruz","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2025.10.006_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.10.006_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525008912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525008912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:54:35Z","timestamp":1784663675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525008912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1542356525008912"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.10.006","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis\/Crohn\u2019s Disease: A Prospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Center Americas Inc. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}